Ocular and systemic antiviral activity of vidarabine.
D000249:Adenosine Monophosphate / Q000031:analogs & derivatives / Q000627:therapeutic use; D000818:Animals; D002644:Chickenpox / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D065306:Corneal Injuries; D006224:Cricetinae; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D005128:Eye Diseases / Q000188:drug therapy*; D006561:Herpes Simplex / Q000188:drug therapy; D006563:Herpes Zoster Ophthalmicus / Q000188:drug therapy; D006801:Humans; D007065:Idoxuridine / Q000494:pharmacology / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D007635:Keratitis, Dendritic / Q000188:drug therapy; D011817:Rabbits; D012899:Smallpox / Q000188:drug therapy; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D014777:Virus Diseases / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects
D000249:Adenosine Monophosphate; D014740:Vidarabine; D007065:Idoxuridine